The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its legacy within the broader industry now presents questions about long-term gains. Generic versions are diminishing patent protection , causing concerns that supporting companies closely tied to Viagra's former standing could be a dangerous move , esp